SIGA Technologies' TPOXX (tecovirimat) Receives FDA Approval for Smallpox
Shots:
- The approval is based on 12 clinical trials results assessing TPOXX (tecovirimat) in 700 patients- demonstrating no adverse effects
- ’ TPOXX (tecovirimat) receives 17-0 votes from FDA’s Antimicrobial Drug Advisory Committee on 05 May- 2018 and also received FDA’s FT- PR & ODD in Dec 2005- 08 Dec- 2017- 07 Jun- 2018 respectively
- TPOXX (tecovirimat) also known as ST-246 is a PO & IV respectively for treating smallpox- developed in collaboration with the US Department of Health & Human Services’ BARDA
Ref: Siga | Image: MacAndrews & Forbes
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com